

RESEARCH ARTICLE

PARKINSON'S DISEASE

Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease

Lena F. Burbulla,^{1,2} Pingping Song,¹ Joseph R. Mazzulli,^{1,2} Enrico Zampese,³ Yvette C. Wong,¹ Sohee Jeon,¹ David P. Santos,¹ Judith Blanz,¹ Carolin D. Obermaier,^{4,5,6} Chelsea Strojny,¹ Jeffrey N. Savas,¹ Evangelos Kiskinis,¹ Xiaoxi Zhuang,⁷ Rejko Krüger,^{4,6,8} D. James Surmeier,³ Dimitri Krainc^{1,2*}

Mitochondrial and lysosomal dysfunction have been implicated in substantia nigra dopaminergic neurodegeneration in Parkinson's disease (PD), but how these pathways are linked in human neurons remains unclear. Here we studied dopaminergic neurons derived from patients with idiopathic and familial PD. We identified a time-dependent pathological cascade beginning with mitochondrial oxidant stress leading to oxidized dopamine accumulation and ultimately resulting in reduced glucocerebrosidase enzymatic activity, lysosomal dysfunction, and α -synuclein accumulation. This toxic cascade was observed in human, but not in mouse, PD neurons at least in part because of species-specific differences in dopamine metabolism. Increasing dopamine synthesis or α -synuclein amounts in mouse midbrain neurons recapitulated pathological phenotypes observed in human neurons. Thus, dopamine oxidation represents an important link between mitochondrial and lysosomal dysfunction in PD pathogenesis.

Parkinson's disease (PD) is the second most common neurodegenerative disorder (1). Although several neuronal populations are affected in PD, substantia nigra pars compacta (SNc) dopaminergic neurons are among the first neurons to degenerate, leading to motor symptoms of PD (2). Familial genes in PD point to both mitochondrial and lysosomal mechanisms as contributors to pathology (1). However, how mutations in components of two distinct essential cellular pathways both result in indistinguishable clinical and pathological phenotypes and finally cause the death of dopaminergic neurons in patients remains unclear. Moreover, because most PD mouse models do not manifest nigral degeneration (3), it is unclear whether this interaction is specific to human neurons.

Loss-of-function mutations in *DJ-1* cause early-onset autosomal recessive PD (4), and *DJ-1* is

known to orchestrate oxidant defenses because its deletion leads to elevated mitochondrial oxidant stress (5). To examine whether elevated mitochondrial oxidant stress triggers downstream pathological phenotypes, fibroblasts from PD patients with a homozygous loss-of-function mutation in *DJ-1* c.192G>C (6) were reprogrammed into induced pluripotent stem cells (iPSCs). These were then differentiated into dopaminergic neurons, which were grown in long-term cultures (fig. S1, A to D, and fig. S2, A and B). For comparison purposes, dopaminergic neurons were also generated from a healthy individual with a single copy of mutated *DJ-1*, idiopathic PD patients without *DJ-1* mutations, and healthy individuals without PD. These neurons had anatomical and electrophysiological characteristics of SNc neurons (7), including robust, low-frequency autonomous pacemaking (fig. S2C) and prominent voltage sag upon brief injection of strong hyperpolarizing currents (fig. S2D). *DJ-1* protein amounts were decreased by ~50% in heterozygous and undetectable in homozygous *DJ-1* mutant neurons (fig. S2E).

Neuromelanin and oxidized dopamine accumulate in dopaminergic neurons from genetic and sporadic PD patients

By day 50 (d50) in culture, mitochondrial oxidant stress was elevated in human homozygous *DJ-1* mutant dopaminergic neurons (Fig. 1A). This increase was seen by using both a genetically encoded, mitochondrial matrix redox sensor (mitroGFP) (5) and by fluorescence measurements

using 2',7'-dichlorodihydrofluorescein diacetate (H₂DCFDA) at d50 and d70 (Fig. 1B). Increased mitochondrial oxidant stress was accompanied by a drop in basal respiration in mutant neurons at d50 (Fig. 1C), suggesting that the observed stress damaged mitochondria.

Homozygous *DJ-1* mutant neurons also accumulated membrane-bound, dense pigmented aggregates consistent with the appearance of neuromelanin (Fig. 1D and fig. S2F). Biochemical properties of these pigments, such as their insolubility to strong detergents, further indicated their similarity to neuromelanin extracted from human brain (8). Neuromelanin is a complex aggregate, including oxidized dopamine, proteins, and lipids (9). To quantify the amount of oxidized dopamine in these neurons, a near infrared fluorescence (nIRF) assay was used (10). Oxidized dopamine progressively increased from d70 to d150 in homozygous *DJ-1* mutant neurons, but not in controls (Fig. 1E). To determine whether the absence of *DJ-1* protein was sufficient to induce this pathological phenotype, clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 was used to generate homozygous *DJ-1* knock out (KO) iPSC-derived neurons (*DJ-1* KO) from controls (fig. S3). These neurons recapitulated the phenotype of *DJ-1* patient neurons, resulting in the progressive accumulation of oxidized dopamine from d70 to d90 (Fig. 1F), as well as decreased basal mitochondrial respiration (Fig. 1G).

Dopaminergic neurons from idiopathic PD patients [iPD1, (11); iPD2, fig. S1, E and F] also manifested a similar phenotype, including decreased basal respiration and oxidized dopamine accumulation, but at later time points (d150, d180) (Fig. 1H and fig. S4A). We observed partial inactivation of *DJ-1* in iPD neurons (fig. S4B), suggesting that decreased *DJ-1* function may contribute to these delayed pathological alterations in iPD neurons (12).

Dopamine-mediated modification of glucocerebrosidase (GCase) contributes to downstream lysosomal dysfunction

Because neuromelanin granules have been found in lysosomes (13), the accumulation of neuromelanin-like aggregates in mutant dopaminergic neurons suggested that lysosomal function might be impaired. Although there was no detectable impairment in lysosomal proteolysis in homozygous *DJ-1* mutant neurons at d70 (Fig. 2A), the activity of the lysosomal enzyme glucocerebrosidase, an important PD risk factor implicated in lysosomal dysfunction in PD (14), was decreased in lysosomal fractions (Fig. 2B). By contrast, there was no drop in the activity of another lysosomal enzyme, α -iduronate-2-sulfatase (α -i-2-sulf). However, lysosomal proteolysis was significantly diminished at a later time point (d180) (Fig. 2A and fig. S5), suggesting that accumulated oxidized dopamine contributed to lysosomal dysfunction in homozygous *DJ-1* mutant neurons. Idiopathic PD neurons exhibited a delayed decrease in GCase activity (d180) compared to *DJ-1* mutant neurons (d70) (Fig. 2C). To determine

¹Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. ²Department of Neurology, Massachusetts General Hospital, Harvard Medical School, MassGeneral Institute for Neurodegeneration, Charlestown, MA 02129, USA. ³Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. ⁴Department for Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research, University of Tübingen, DZNE, German Centre for Neurodegenerative Diseases, Tübingen, Germany. ⁵Graduate School for Cellular and Molecular Neuroscience, University of Tübingen, Germany. ⁶Clinical and Experimental Neuroscience, Luxembourg Center for Systems Biomedicine, University of Luxembourg, Luxembourg. ⁷Department of Neurobiology, University of Chicago, Chicago, IL 60637, USA. ⁸Centre Hospitalier Luxembourg, Luxembourg. *Corresponding author. Email: dkrainc@nm.org

Fig. 1. Neuromelanin and oxidized dopamine accumulate in PD patient dopaminergic neurons.

(A) Neuronal expression of mito-roGFP and quantification of relative oxidation in control (ctrl) and homozygous *DJ-1* mutant (hom) neurons at d50 ($n = 3$). Scale bar, 10 μm .

(B) H_2DCFDA fluorescence in neurons at d50 and d70 ($n = 3$).

(C) Oxygen consumption rate (OCR) in neurons under basal conditions at d50 ($n = 3$).

(D) Electron microscopy (EM) image of neuromelanin deposition (arrow) in homozygous *DJ-1* mutant neuron at d90. Scale bar, 200 nm.

(E and F) Oxidized dopamine (DA) by nIRF at d90 in (E) homozygous *DJ-1* mutant [hom(1) and hom(2)] neurons and controls, quantification at d70, d90, and d150 ($n = 3$), het for heterozygous, or

(F) *DJ-1* KO and isogenic control neurons and quantification at d70 and d90 ($n = 3$ or 4).

(G) OCR in *DJ-1* KO neurons and isogenic controls under basal conditions at d50 ($n = 12$).

(H) Oxidized dopamine in control and two idiopathic PD (iPD1, iPD2) neurons at d70, d150, and d180 ($n = 3$). Quantification for each iPD line is normalized to control for each time point. Equal protein


if other forms of genetic PD might show similar alterations, we generated iPSC-derived neurons from PD patients with homozygous mutations in the *parkin*, *PINK1*, and *LRK2* (15, 16) genes and neurons carrying triplication of wild-type (WT) α -synuclein (17). We observed a similar increase in oxidized dopamine across all genotypes (fig. S4, C and E to G) as well as decreased GCCase activity in *parkin* mutant neurons (fig. S4D), further suggesting the presence of common phenotypes across both sporadic and familial forms of PD.

Because elevated oxidant stress and oxidized dopamine were detected concomitantly with decreased GCCase activity (Figs. 1 and 2, A to C), we next sought to determine if reduced GCCase

function could have resulted from oxidation of the protein. Indeed, the activity of recombinant GCCase, but not α -i-2-sulf, was reduced by incubation with dopamine (Fig. 2D). Using in-gel nIRF, dopamine incubation was found to modify GCCase compared to α -i-2-sulf, and these changes were blocked upon antioxidant treatment with *N*-acetylcysteine (NAC) (Fig. 2, E and F). Using tandem mass spectrometry (MS/MS), we identified cysteine residues in the catalytic site of GCCase that were modified by dopamine quinones, reactive oxidized forms of dopamine (Fig. 2G). These results suggested that oxidant stress directly modifies and disrupts GCCase enzymatic activity and contributes to lysosomal dysfunction in PD neurons.

Mitochondrial antioxidants and calcium modulators attenuate the toxic cascade in *DJ-1* mutant dopaminergic neurons

We found that long-term treatment with either the mitochondrial-targeted antioxidant mito-TEMPO or NAC blunted the accumulation of oxidized dopamine and improved lysosomal GCCase activity and proteolysis (Fig. 3, A to D). Furthermore, because increased Ca^{2+} entry through Cav1 voltage-gated calcium channels enhances mitochondrial oxidant stress and dopamine synthesis (5, 18), we tested whether the Cav1 channel antagonist isradipine (19) or the calcium-dependent serine-threonine phosphatase calcineurin inhibitor FK506 (20) could also regulate dopamine oxidation. Both isradipine and FK506 significantly



concentrations were used for nIRF assays. Error bars, means \pm SEM. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; Student's *t* test (A), (B), and (F) to (H) or one-way analysis of variance (ANOVA) with Tukey post hoc test (C) and (E).




Fig. 2. Dopamine-mediated modification of GCase and lysosomal dysfunction in PD patient neurons. (A) Lysosomal proteolysis in control (ctrl) and homozygous *DJ-1* mutant (hom) neurons at d70 and d180 ($n = 3$). (B) GCase and α -i-2-sulf activity in lysosomal fractions from control and homozygous *DJ-1* mutant neurons at d70 ($n = 3$). (C) GCase activity in lysosomal fractions from control and idiopathic PD (iPD) neurons at d70 and d180 ($n = 3$). (D) Recombinant GCase and α -i-2-sulf activity after incubation with DA or phosphate-buffered saline (PBS) ($n = 5$).

(E and F) Oxidized DA by in-gel nIRF of (E) recombinant GCase or (F) α -i-2-sulf after incubation with DA, DA+NAC, or PBS. Coomassie brilliant blue (CBB) was used to visualize total protein. (G) MS/MS spectrum of GCase treated with DA. Modified cysteine is indicated with mass adduct in parentheses. Prominent b (blue) and y (red) ions and fragments containing the additional mass (bold) are indicated. Error bars, means \pm SEM. * $P < 0.05$; *** $P < 0.001$; one-way ANOVA with Tukey post hoc test (A) or Student's t test (B) to (D).

diminished the accumulation of oxidized dopamine (Fig. 3E), highlighting the importance of Ca^{2+} in regulating dopamine oxidation in *DJ-1* mutant neurons.

Oxidant stress has also been found to drive α -synuclein aggregation, the primary structural component of Lewy bodies and a pathological hallmark of PD (21). Furthermore, dopamine adducts can modify α -synuclein and promote its aggregation, and a recent study reports that loss of DJ-1 function is associated with Lewy body pathology (22). Soluble α -synuclein was elevated at d70 in both homozygous *DJ-1* mutant and CRISPR-Cas9-generated *DJ-1* KO neurons (Fig. 3, F and G). We observed a time-dependent increase in oxidized, insoluble α -synuclein from d70 to d100 in mutant neurons (fig. S6, A and B), but not in heterozygous *DJ-1* neurons or controls. NAC treatment also decreased α -synuclein accumulation in *DJ-1* mutant neurons (Fig. 3H and fig. S6, C and D). To determine whether dopamine contributed to this phenotype, neurons were treated with α -methyl- p -tyrosine (AMPT), which competitively inhibits tyrosine hydroxylase and prevents dopamine synthesis. AMPT treatment diminished mitochondrial oxidant stress, as well as oxidized dopamine (Fig. 3, I and J), and reduced soluble α -synuclein amounts in *DJ-1* mutant neurons (Fig. 3K), suggesting that mitochondrial

oxidant stress and oxidized dopamine contribute to α -synuclein accumulation in PD neurons.

Increasing dopamine or α -synuclein in mouse neurons recapitulates pathology in human neurons

We next examined whether this toxic cascade observed in human PD neurons also occurred in SNc dopaminergic neurons from PD mouse models. In contrast to human neurons, SNc from *DJ-1* KO mice showed negligible amounts of oxidized dopamine at 3 and 12 months of age (Fig. 4, A and B). In addition, soluble and insoluble α -synuclein amounts were normal in SNc from *DJ-1* KO mice (Fig. 4C and fig. S7, A and B), and lysosomal GCase activity was not altered (Fig. 4G) compared to WT mice. Moreover, tyrosine hydroxylase (TH) immunoreactivity in the SNc (Fig. 4I) was not decreased in *DJ-1* KO mice, indicating a lack of nigral pathology.

Because mutations in α -synuclein that result in its accumulation lead to familial PD, we then asked whether increasing amounts of mutant α -synuclein in vivo might drive this toxic cascade in *DJ-1* KO mice. We generated mice with both dopamine neuron-specific overexpression of human α -synuclein A53T (23) and constitutive DJ-1 deficiency ($\text{DA}_{\text{SYN53}} \times \text{DJ-1 KO}$) (fig. S8A). These mice showed elevated amounts of oxidized dopamine in

nigral neurons (Fig. 4D) and decreased lysosomal GCase activity (Fig. 4E) compared to *DJ-1* KO mice. Heterozygous expression of DJ-1 in DA_{SYN53} mice was sufficient to ameliorate pathological phenotypes observed in $\text{DA}_{\text{SYN53}} \times \text{DJ-1 KO}$ mice (fig. S8, B to D) suggesting that a combination of α -synuclein accumulation and loss of DJ-1 contributes to nigral degeneration in mice.

We next investigated whether increasing dopamine amounts in vivo might also trigger pathology in mice. Chronic feeding of WT or *DJ-1* KO mice with levodopa (L -dopa)-supplemented chow led to oxidized dopamine accumulation in the nigra (Fig. 4F and fig. S7C). Treatment with L -dopa in *DJ-1* KO mice, but not in WT mice, was sufficient to disrupt SNc GCase enzymatic activity (Fig. 4G), increase α -synuclein accumulation (Fig. 4H and fig. S7D), and trigger the loss of dopaminergic neurons (Fig. 4I and fig. S7E). Treatment with L -dopa had no effect on homocysteine amounts (fig. S7F).

Altered calcium and dopamine metabolism contribute to differences between human and mouse neurons

To directly compare human neurons with mouse neurons, we extended these experiments to mouse iPSC-derived dopaminergic neurons generated from *DJ-1* KO and WT fibroblasts (fig. S9A).




Fig. 3. Mitochondrial antioxidants and calcium modulators attenuate the toxic cascade in DJ-1 mutant dopaminergic neurons. (A and B) Oxidized DA in homozygous DJ-1 mutant (hom) neurons treated with (A) mito-TEMPO or (B) NAC compared to vehicle (veh) at d70 ($n = 3$).

(C) GCase and α -i-2-sulf activity in lysosomal fractions from homozygous DJ-1 mutant neurons treated with mito-TEMPO or vehicle at d70 ($n = 3$). (D) Lysosomal proteolysis in homozygous DJ-1 mutant neurons treated with NAC or vehicle at d180 ($n = 3$). a.u., arbitrary units. (E) Oxidized DA in homozygous DJ-1 mutant, heterozygous DJ-1 carrier (het), and control neurons treated with isradipine, FK506, or vehicle (DMSO, dimethyl sulfoxide) at d90 ($n = 3$ to 6). (F and G) Immunoblot analysis of α -synuclein (syn211 antibody) at d70 in Triton X-100 (T)-soluble neuronal lysates from (F) control,

heterozygous DJ-1 carrier, and two homozygous DJ-1 mutant lines ($n = 4$) or (G) a gene-edited DJ-1 KO line ($n = 3$ or 4). β -III-tubulin, synapsin, and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) were used as loading controls. (H) T-insoluble α -synuclein (C20 antibody) at d70 in homozygous DJ-1 mutant neurons treated with NAC or vehicle. CBB was used as a loading control ($n = 4$). (I) Homozygous DJ-1 mutant neurons expressing mito-roGFP treated with AMPT at d50 ($n = 3$). (J and K) Homozygous DJ-1 mutant neurons treated with AMPT and analyzed at d70 for (J) oxidized DA by nRF ($n = 3$) or (K) T-soluble α -synuclein (syn211 antibody). GAPDH and β -III-tubulin were used as loading controls ($n = 3$). Treatment was applied for 30 days (A) to (C), (E), and (H) to (K) or 140 days (D). Error bars, means \pm SEM. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; Student's t test (A) to (D) and (G) to (K) or one-way ANOVA with Tukey post hoc test (E) and (F).




Fig. 4. Increasing dopamine synthesis or amounts of α -synuclein in mouse midbrain neurons recapitulates pathological phenotypes observed in human neurons. (A and B) Oxidized DA in substantia nigra (SNc) from *DJ-1* KO and WT mice at 3 and 12 months compared to human control neurons at d70. (C) T-soluble α -synuclein (C20 antibody) in SNc of WT and *DJ-1* KO mice. GAPDH and NSE (neural-specific enolase) loading controls ($n = 3$ per group). (D and E) SN from *DJ-1* KO and $DA_{SYN53} \times DJ-1$ KO mice analyzed at 8 months of age for (D) oxidized DA and (E) GCase activity ($n = 5$ per group). (F to I) WT and *DJ-1* KO mice were fed L-dopa-supplemented or vehicle-treated chow for 6 months and substantia nigra analyzed at 14 months for (F) oxidized DA ($n = 3$ or 4 per group), (G) GCase activity ($n = 3$ or 4 per group), (H) T-insoluble α -synuclein (C20 and syn202 antibodies) with CBB loading control ($n = 3$ or 4 per group), and (I) number of DAB (3,3'-diaminobenzidine)-stained TH-positive neurons ($n = 3$ per group). Equal protein concentrations were used for nIRF assays. Error bars, means \pm SEM. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; Student's t test (C) to (E), and (H), or one-way ANOVA with Tukey post hoc test (B), (F), (G), and (I). n.s., not significant.

Consistent with the *in vivo* results, *DJ-1* KO mouse neurons did not manifest increased amounts of oxidized dopamine at d40, d70, or d90 (Fig. 5A). However, treatment of these neurons with L-dopa resulted in increased oxidized dopamine (Fig. 5B), disrupted lysosomal GCase activity (Fig. 5C), and decreased neuronal survival (fig. S9B). There were no pathological changes observed in L-dopa-treated mouse WT neurons (Fig. 5, B and C), further suggesting that both mitochondrial oxidant stress and increased oxidized dopamine contribute to neurotoxicity of dopaminergic neurons.

Using high-performance liquid chromatography (HPLC) for detection of dopamine and

its metabolites, we found that human control neurons showed elevated amounts of dopamine compared to mouse WT neurons (Fig. 5F), suggesting a difference in dopamine metabolism between species. Consistent with this notion is the observation that L-dopa treatment was sufficient to increase oxidized dopamine in human control (fig. S10), but not mouse WT, neurons (Fig. 5B). Dopamine can either be converted into nontoxic downstream metabolites, including 3,4-dihydroxyphenylacetic acid (DOPAC), or form toxic dopamine quinones and aminochrome, which are normally sequestered in neuromelanin (9). We hypothesized that increased oxidative

stress in *DJ-1* KO mouse neurons may preferentially result in oxidized dopamine and neuromelanin upon treatment with L-dopa. Although the baseline amounts of total dopamine were comparable between mouse WT and *DJ-1* mutant neurons (Fig. 5G), mutant neurons showed a dramatically decreased DOPAC/dopamine ratio when treated with L-dopa compared to WT neurons (Fig. 5H). Thus, decreased dopamine degradation into nontoxic metabolites may be responsible for the accumulation of oxidized dopamine.

Because the calcineurin inhibitor FK506 diminished the accumulation of oxidized dopamine




Fig. 5. Alterations in calcium homeostasis and dopamine metabolism contribute to intrinsic differences between human and mouse dopaminergic neurons. (A to C) WT and *DJ-1* KO mouse iPSC-derived dopaminergic neurons were analyzed for (A) oxidized DA at d40, d70, and d90 (50 μ M and 500 μ M standards shown) or treated with L-dopa or vehicle and analyzed at d55 for (B) oxidized DA ($n = 3$) and (C) lysosomal GCase activity ($n = 3$). (D to F) Control human and WT mouse iPSC-derived dopaminergic neurons analyzed for (D) T-soluble calcineurin ($n = 5$ or 6), (E) calcineurin activity ($n = 5$), and (F) DA amounts by HPLC [$n = 5$ (mouse); $n = 10$ (human)]. HPLC chromatogram in a 4 μ M standard sample is shown. Dihydroxybenzylamine (DHBA) was used as an internal standard. (G) WT and *DJ-1* KO mouse iPSC-derived dopaminergic neurons were analyzed for total DA content at d55 ($n = 5$). (H) The ratio of DOPAC/DA for WT and *DJ-1* KO mouse iPSC-derived dopaminergic neurons treated with L-dopa ($n = 8$). Equal protein concentration was used in nIRF assays. Error bars, means \pm SEM. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; Student's t test (D) to (H) or one-way ANOVA with Tukey post hoc test (B) and (C). n.s., not significant.

(Fig. 3E), we examined if calcineurin might be altered between mice and humans. Control human neurons showed both increased protein amounts and activity of calcineurin (Fig. 5, D and E) compared to mouse WT neurons, further suggesting that alterations in calcium homeostasis may also contribute to interspecies differences in dopamine metabolism.

Discussion

Here we have found that elevated mitochondrial oxidant stress in human SNc dopaminergic neurons triggers a dopamine-dependent toxic

cascade leading to lysosomal dysfunction and α -synuclein accumulation—causally linking three major pathological features of PD. This discovery complements previous work demonstrating that lysosomal dysfunction leads to deficits in mitophagy and the buildup of dysfunctional mitochondria (24) and raises the possibility of a pathogenic positive feedback between these two organelles. The pathogenic cascade from mitochondria to lysosomes was only evident in human—not mouse—dopaminergic neurons. This species difference was inferred to be a consequence of higher amounts of dopamine in hu-

man neurons on the basis of several lines of evidence, including the selective accumulation of neuromelanin in human neurons and the ability of L-dopa, the synthetic precursor of dopamine, to induce the pathological cascade in mouse dopaminergic neurons modeling PD. In addition, our data also suggest that increased cytosolic dopamine contributes to elevated mitochondrial oxidant stress, indicating a vicious cycle of dopamine and mitochondrial oxidation in human midbrain neurons.

Although increased α -synuclein inhibits GCase trafficking and lysosomal function in various cell types (19), our data suggest that increased oxidant stress and dopamine adduct formation modified the catalytic site of GCase and lowered its activity preferentially in midbrain dopaminergic neurons. Because similar alterations in oxidized dopamine and GCase were seen in neurons obtained from patients with idiopathic and familial PD, we propose that this mechanism applies across various forms of PD. In support of this notion, we showed that elevation of α -synuclein in the substantia nigra of *DJ-1* KO mice also resulted in increased oxidized dopamine, diminished activity of GCase, and neurodegeneration.

Our long-term midbrain cultures demonstrated that early treatment with mitochondrial antioxidants reduced downstream accumulation of oxidized dopamine and α -synuclein and rescued lysosomal dysfunction, highlighting the importance of early therapeutic intervention in the pathogenic cascade. The inherent differences between human and mouse dopaminergic neuronal vulnerability emphasize the value of studies in human neurons to identify pathways and targets for therapeutic development in PD and related synucleinopathies.

REFERENCES AND NOTES

1. L. V. Kalia, A. E. Lang, *Lancet* **386**, 896–912 (2015).
2. D. J. Surmeier, J. A. Obeso, G. M. Halliday, *Nat. Rev. Neurosci.* **18**, 101–113 (2017).
3. T. M. Dawson, H. S. Ko, V. L. Dawson, *Neuron* **66**, 646–661 (2010).
4. V. Bonifati et al., *Science* **299**, 256–259 (2003).
5. J. N. Guzman et al., *Nature* **468**, 696–700 (2010).
6. G. Krebiel et al., *PLoS ONE* **5**, e9367 (2010).
7. J. N. Guzman, J. Sánchez-Padilla, C. S. Chan, D. J. Surmeier, *J. Neurosci.* **29**, 11011–11019 (2009).
8. L. Zecca et al., *Proc. Natl. Acad. Sci. U.S.A.* **105**, 17567–17572 (2008).
9. D. Sulzer et al., *Proc. Natl. Acad. Sci. U.S.A.* **97**, 11869–11874 (2000).
10. J. R. Mazzulli, L. F. Burbulla, D. Krainc, H. Ischiropoulos, *Anal. Chem.* **88**, 2399–2405 (2016).
11. J. R. Mazzulli et al., *J. Neurosci.* **36**, 7693–7706 (2016).
12. J. Choi et al., *J. Biol. Chem.* **281**, 10816–10824 (2006).
13. S. Plum et al., *Sci. Rep.* **6**, 37139 (2016).
14. J. R. Mazzulli et al., *Cell* **146**, 37–52 (2011).
15. J. D. Miller et al., *Cell Stem Cell* **13**, 691–705 (2013).
16. O. Cooper et al., *Sci. Transl. Med.* **4**, 141ra90 (2012).
17. J. R. Mazzulli, F. Zunke, O. Isacson, L. Studer, D. Krainc, *Proc. Natl. Acad. Sci. U.S.A.* **113**, 1931–1936 (2016).
18. E. V. Mosharov et al., *Neuron* **62**, 218–229 (2009).
19. Parkinson Study Group, *Mov. Disord.* **28**, 1823–1831 (2013).
20. G. Caraveo et al., *Proc. Natl. Acad. Sci. U.S.A.* **111**, E3544–E3552 (2014).
21. Y. C. Wong, D. Krainc, *Nat. Med.* **23**, 1–13 (2017).
22. R. Taipa et al., *Brain* **139**, 1680–1687 (2016).
23. L. Chen, Z. Xie, S. Turkson, X. Zhuang, *J. Neurosci.* **35**, 890–905 (2015).

24. M. E. Gegg, A. H. Schapira, *Neurobiol. Dis.* **90**, 43–50 (2016).

ACKNOWLEDGMENTS

We are grateful to D. Sulzer, E. V. Mosharov, J. W. Shim, G. Caraveo, and J. Zheng for helpful discussions and suggestions. We thank the Northwestern Stem Cell Core Facility for the generation of mouse iPSC lines (supported by P30 NS081774). We are grateful to K. Hamada as well as M. K. V. Suresh for technical assistance and C. Leong for help with the assessment of off-target gene editing in the CRISPR-edited lines. The mito-roGFP construct

was a gift from P. Schumacker (Northwestern University). This work was supported by NIH (grants R01NS076054 to D.K., NS047085 to D.J.S., R01NS092823 to J.R.M., R00DC013805-02 to J.N.S., and T32NS041234 and F32NS101778 to Y.C.W.); The JPB Foundation and The Michael J. Fox and IDP Foundations to D.J.S.; German Academic Exchange Service to L.F.B.; Les Turner ALS Foundation, Target ALS, and MDA to E.K.; and the German Research Council grant KR2119/8-1 and the Fond National de Recherche PEARL program grant FNR/P13/6682797 to R.K. All data necessary to support this paper's conclusions are available in the supplementary materials.

SUPPLEMENTARY MATERIALS

www.sciencemag.org/content/357/6357/1255/suppl/DC1
Materials and Methods
Supplementary Text
Figs. S1 to S10
References (25–36)

7 February 2017; resubmitted 10 August 2017
Accepted 23 August 2017
Published online 7 September 2017
10.1126/science.aam9080

Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease

Lena F. Burbulla, Pingping Song, Joseph R. Mazzulli, Enrico Zampese, Yvette C. Wong, Sohee Jeon, David P. Santos, Judith Blanz, Carolin D. Obermaier, Chelsea Strojny, Jeffrey N. Savas, Evangelos Kiskinis, Xiaoxi Zhuang, Rejko Krüger, D. James Surmeier and Dimitri Krainc

Science **357** (6357), 1255-1261.
DOI: 10.1126/science.aam9080originally published online September 7, 2017

Human-derived neurons provide the answers

Pathways involved in energy metabolism and removal of cellular debris by lysosomes play an important role in protecting our brain from degeneration in Parkinson's disease. Burbulla *et al.* identified a toxic cascade of mitochondrial and lysosomal dysfunction in human neurons derived from patients with Parkinson's. The dysfunction was mediated by accumulation of oxidized dopamine and α -synuclein, but it was not found in Parkinson's mouse models, owing to species-specific differences in dopamine metabolism. Inherent species-specific differences between human and mouse neurons emphasize the value of studying human neurons to identify relevant targets for treatment of Parkinson's disease and related synucleinopathies.

Science, this issue p. 1255

ARTICLE TOOLS

<http://science.sciencemag.org/content/357/6357/1255>

SUPPLEMENTARY MATERIALS

<http://science.sciencemag.org/content/suppl/2017/09/06/science.aam9080.DC1>

REFERENCES

This article cites 36 articles, 13 of which you can access for free
<http://science.sciencemag.org/content/357/6357/1255#BIBL>

PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)